In this study, we found that BRD7 could inhibit the expression of PD-L1 in tumor cells by downregulating the activity of the PI3K/AKT signaling pathway, thereby inhibiting its binding to PD-1 on T cells, restoring the cytotoxic function of CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.